CoChat

Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis

Open access

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 67 of the 85 sources its claims cite were checked for support.

Abstract

A cytoskeleton-associated protein regulates microglial function and affects Alzheimer’s disease phenotypes.

Overview

CoChat Summary

TL;DR

Deletion of the Abi3 locus in 5XFAD mice exacerbated Aβ amyloidosis, increased amyloid plaques, reduced plaque-associated microglia, altered immune gene expression, impaired microglial migration/phagocytosis, and worsened hippocampal LTP. The findings suggest ABI3 regulates microglial function and Aβ pathology in a mouse model of Alzheimer’s disease–like amyloidosis.

Key findings

  • In 8-month-old 5XFAD mice, loss of Abi3 increased cortical Aβ in a gene dose–dependent manner: insoluble Aβ40 rose 1.9- and 2.7-fold in male Abi3+/− and Abi3−/− mice versus Abi3+/+, and insoluble Aβ42 rose 1.7- and 2.3-fold; soluble Aβ40 rose 1.4- and 2.1-fold, and soluble Aβ42 rose 1.4- and 1.6-fold. Female Abi3−/− mice also had increased cortical insoluble Aβ40 (2.2-fold) and Aβ42 (1.5-fold), and soluble Aβ40 (1.8-fold) and Aβ42 (1.6-fold).
  • Amyloid plaque load was increased in Abi3+/− and Abi3−/− cortices, and the number of Iba1+ cells around X34+ plaques was significantly decreased, while overall Iba1+ area did not differ.
  • Transcriptomic analyses identified immune response as a top dysregulated pathway; C1qa, Ctss, complement genes, and other immune genes were up-regulated, and chemokines CCL24, CXCL10, CCL3, and CXCL16 were increased while CCL25 was decreased in Abi3−/− brains.
  • Targeted scRNA-seq showed a marked microglial subpopulation shift: cluster 0 decreased from 38.34% in Abi3+/+ to 8.47% in Abi3−/−, while cluster 1 increased from 7.52% to 37.47%; cluster 1 was more DAM-like and immune-response enriched. LTP was significantly decreased in Abi3+/− and Abi3−/− mice compared with Abi3+/+.

Methods

  • Abi3−/− mice were crossed with 5XFAD mice to generate 5XFAD;Abi3+/+, Abi3+/−, and Abi3−/− mice; both sexes were analyzed separately. Ages were 8 or 4.5 months for biochemical experiments, 6 months for electrophysiology, and 9 months for scRNA-seq.
  • Main assays included Aβ electrochemiluminescence, immunohistochemistry (82E1, X34, Iba1), Western blot, qPCR, NanoString Mouse AD and Neuroinflammation panels, bulk RNA-seq, targeted scRNA-seq (BD Rhapsody Mouse Immune Response Panel, 397 genes), Bio-Plex chemokine assay, scratch-wound migration assay, phagocytosis assay, and hippocampal LTP recordings.
  • Human ABI3 protein was analyzed using a Mount Sinai Brain Bank proteomics dataset from parahippocampal cortices of AD cases (N = 39) and cognitively normal controls (N = 23), with correction for cell-type composition.

Limitations

  • The paper states that it cannot determine whether the inflammatory and microglial transcriptomic changes are direct consequences of Abi3 loss or secondary to increased Aβ pathology, and that deleting Abi3 before amyloid accumulation may not predict the effect of decreasing ABI3 after amyloid accumulation.
  • The paper notes that the targeted scRNA-seq panel contains only 397 genes, so changes in other genes or cell types may have been missed; it also notes possible disruption of neighboring genes, especially Gngt2, by the Abi3 knockout strategy.
  • The paper states that no good commercially available ABI3 antibody detects endogenous ABI3 protein, so deletion was confirmed by qPCR; the exact mechanism by which Abi3 regulates synaptic function was not identified.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.abe3954

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Aβ accumulation increases in the cortex and hippocampus of male and female Abi3−/− mice. Insoluble Aβ40 and Aβ42 levels were measured in the guanidine fraction (A and B) and soluble Aβ40 and Aβ42 levels were measured in the phosphate-buffered saline (PBS) fraction (C and D) of 5XFAD mouse cortices using Meso Scale Discovery (MSD) electrochemiluminescence assay. Insoluble Aβ40 (A) and Aβ42 (B) levels were increased in the cortices of 8-month-old male Abi3+/− and Abi3−/− mice compared to Abi3+/+ mice. Soluble Aβ40 (C) and Aβ42 (D) levels were increased in the cortices of 8-month-old male Abi3−/− mice compared to Abi3+/+ mice. Insoluble Aβ40 (E) and Aβ42 (F) levels were increased in the cortices of 8-month-old female Abi3−/− mice compared to Abi3+/+ mice. Soluble Aβ40 (G) and Aβ42 (H) levels were increased in the cortices of 8-month-old female Abi3−/− mice compared to Abi3+/+ mice. (I to L) Insoluble Aβ40 and Aβ42 levels were measured in the hippocampus. Male Abi3−/− mice accumulated higher levels of (I) Aβ40 and (J) Aβ42. Similarly, female Abi3−/− mice had higher levels of (K) Aβ40 and (L) Aβ42 (Abi3+/+, n = 20 male and 20 female; Abi3+/−, n = 12 male and 20 female; Abi3−/−, n = 14 male and 18 female). Data represent means ± SEM. One-way analysis of variance (ANOVA) and Tukey’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. See also fig. S3.
Fig. 1. Aβ accumulation increases in the cortex and hippocampus of male and female Abi3−/− mice. Insoluble Aβ40 and Aβ42 levels were measured in the guanidine fraction (A and B) and soluble Aβ40 and Aβ42 levels were measured in the phosphate-buffered saline (PBS) fraction (C and D) of 5XFAD mouse cortices using Meso Scale Discovery (MSD) electrochemiluminescence assay. Insoluble Aβ40 (A) and Aβ42 (B) levels were increased in the cortices of 8-month-old male Abi3+/− and Abi3−/− mice compared to Abi3+/+ mice. Soluble Aβ40 (C) and Aβ42 (D) levels were increased in the cortices of 8-month-old male Abi3−/− mice compared to Abi3+/+ mice. Insoluble Aβ40 (E) and Aβ42 (F) levels were increased in the cortices of 8-month-old female Abi3−/− mice compared to Abi3+/+ mice. Soluble Aβ40 (G) and Aβ42 (H) levels were increased in the cortices of 8-month-old female Abi3−/− mice compared to Abi3+/+ mice. (I to L) Insoluble Aβ40 and Aβ42 levels were measured in the hippocampus. Male Abi3−/− mice accumulated higher levels of (I) Aβ40 and (J) Aβ42. Similarly, female Abi3−/− mice had higher levels of (K) Aβ40 and (L) Aβ42 (Abi3+/+, n = 20 male and 20 female; Abi3+/−, n = 12 male and 20 female; Abi3−/−, n = 14 male and 18 female). Data represent means ± SEM. One-way analysis of variance (ANOVA) and Tukey’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. See also fig. S3.CC BY · PubMed Central
Fig. 2. Deletion of Abi3 gene locus increases amyloid plaques in 5XFAD mouse cortices. (A) Representative images showing coronal brain sections from 8-month-old Abi3+/+, Abi3+/−, and Abi3−/− mice stained with Aβ-specific 82E1 antibody. Scale bars, 300 μm. (B) Quantification of 82E1-positive Aβ plaque area and (C) the number of Aβ plaques in the cortices of male mice (n = 12 mice per genotype). (D) Quantification of 82E1-positive Aβ plaque area and (E) the number of Aβ plaques in the cortices of female mice (n = 18 mice per genotype). (F) Representative images of brain sections from 8-month-old Abi3+/+, Abi3+/−, and Abi3−/− mice stained with X34 dye that detects fibrillar plaques. Scale bars, 200 μm. The images are converted to grayscale, and white dots represent X34+ plaques. (G) Quantification of X34+ fibrillar plaque area and (H) the number of the plaques in male mouse cortices (n = 12 mice per genotype). (I) Quantification of X34+ fibrillar plaque area and (J) the number of the plaques in female mouse cortices (n = 18 mice per genotype). Data represent means ± SEM. One-way ANOVA and Tukey’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 2. Deletion of Abi3 gene locus increases amyloid plaques in 5XFAD mouse cortices. (A) Representative images showing coronal brain sections from 8-month-old Abi3+/+, Abi3+/−, and Abi3−/− mice stained with Aβ-specific 82E1 antibody. Scale bars, 300 μm. (B) Quantification of 82E1-positive Aβ plaque area and (C) the number of Aβ plaques in the cortices of male mice (n = 12 mice per genotype). (D) Quantification of 82E1-positive Aβ plaque area and (E) the number of Aβ plaques in the cortices of female mice (n = 18 mice per genotype). (F) Representative images of brain sections from 8-month-old Abi3+/+, Abi3+/−, and Abi3−/− mice stained with X34 dye that detects fibrillar plaques. Scale bars, 200 μm. The images are converted to grayscale, and white dots represent X34+ plaques. (G) Quantification of X34+ fibrillar plaque area and (H) the number of the plaques in male mouse cortices (n = 12 mice per genotype). (I) Quantification of X34+ fibrillar plaque area and (J) the number of the plaques in female mouse cortices (n = 18 mice per genotype). Data represent means ± SEM. One-way ANOVA and Tukey’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 3. Deletion of Abi3 locus decreases the number of plaque-associated microglia. (A) Representative images showing coronal brain sections stained with the microglial marker Iba1 antibody (green) and X34 fluorescent dye (blue). Scale bars, 50 μm. (B) The percent of area covered by Iba1 staining was quantified in the cortices of female mice. Area covered by Iba1+ cells did not differ between the genotypes. (C) The number of Iba1+ cells overlapping with X34+ plaques was quantified based on the size of each plaque. In each group, the number of Iba1+ cells per plaque was decreased in Abi3−/− mice compared to Abi3+/+ mice (n = 18 per genotype). Data represent means ± SEM. One-way ANOVA and Tukey’s multiple comparisons test; **P < 0.01 and ***P < 0.001. See also fig. S6.
Fig. 3. Deletion of Abi3 locus decreases the number of plaque-associated microglia. (A) Representative images showing coronal brain sections stained with the microglial marker Iba1 antibody (green) and X34 fluorescent dye (blue). Scale bars, 50 μm. (B) The percent of area covered by Iba1 staining was quantified in the cortices of female mice. Area covered by Iba1+ cells did not differ between the genotypes. (C) The number of Iba1+ cells overlapping with X34+ plaques was quantified based on the size of each plaque. In each group, the number of Iba1+ cells per plaque was decreased in Abi3−/− mice compared to Abi3+/+ mice (n = 18 per genotype). Data represent means ± SEM. One-way ANOVA and Tukey’s multiple comparisons test; **P < 0.01 and ***P < 0.001. See also fig. S6.CC BY · PubMed Central
Fig. 4. Knockdown of ABI3 decreases migration of microglia in vitro. (A) HMC3 microglia cells were transfected with ABI3-targeting or negative control siRNAs. ABI3 siRNA decreased mRNA level of ABI3 by 72% in HMC3 cells (n = 3 per group). (B) A scratch was made in the middle of the wells with WoundMaker tool. Cell confluency within the scratch area was analyzed 72 hours after using the IncuCyte S3. Yellow area shows initial scratch area, and green area shows the scratch area without cells. (C) Wound confluency was decreased in ABI3 knockdown group. (D) Relative wound density was decreased in ABI3-silenced microglia (n = 5 per group). Data represent means ± SEM. Unpaired t test; **P < 0.01 and ***P < 0.001.
Fig. 4. Knockdown of ABI3 decreases migration of microglia in vitro. (A) HMC3 microglia cells were transfected with ABI3-targeting or negative control siRNAs. ABI3 siRNA decreased mRNA level of ABI3 by 72% in HMC3 cells (n = 3 per group). (B) A scratch was made in the middle of the wells with WoundMaker tool. Cell confluency within the scratch area was analyzed 72 hours after using the IncuCyte S3. Yellow area shows initial scratch area, and green area shows the scratch area without cells. (C) Wound confluency was decreased in ABI3 knockdown group. (D) Relative wound density was decreased in ABI3-silenced microglia (n = 5 per group). Data represent means ± SEM. Unpaired t test; **P < 0.01 and ***P < 0.001.CC BY · PubMed Central
Fig. 5. Deletion of Abi3 locus alters immune response genes in 5XFAD mice. DEGs were identified in the cortices of 8-month-old male Abi3−/− mice compared to Abi3+/+ mice using the nCounter NanoString mouse (A to C) AD panel and (D to F) Neuroinflammation panel (n = 6 per genotype). Volcano plots (A and D) demonstrate the fold change (x axis) and statistical significance level expressed as the −log10 P value (y axis). The red dots represent genes up-regulated significantly more than 1.5-fold in Abi3−/− mice compared to Abi3+/+ mice. Heatmaps demonstrate the DEGs up-regulated more than 1.5-fold in Abi3−/− mice compared to Abi3+/+ mice using the (B) AD and (E) Neuroinflammation panels. Gene ontology (GO) analyses were performed for DEGs in the (C) AD panel and (F) Neuroinflammation panel using the MetaCore software. (G) Pathmap analysis was performed using MetaCore. Up-regulated genes in our dataset are shown with red circles, and down-regulated genes are shown with blue circles in the pathmap. Green arrows between nodes represent activation, while gray arrows represent interaction with no specific direction of effect. Enriched genes involved in inflammatory processes are shown in red rectangles. See also fig. S7. IL6RA, interleukin-6 receptor α; HDL, high-density lipoprotein; M-CSF, macrophage colony-stimulating factor; TNF, tumor necrosis factor; PLC-γ, phospholipase C–γ; APG7, autophagy related 7; APOA1, apolipoprotein A1; BLNK, B cell linker; C1qb, complement C1q B chain; DAP12, TYRO protein tyrosine kinase-binding protein; GATA-4, GATA binding protein 4; HDAC1, histone deacetylase 1; ITGB5, integrin subunit beta 5; MafB, MAF BZIP transcription factor B; MELC, myosin essential light chain; Rac1, Rac family small GTPase 1; RIPK1, receptor-interacting serine/threonine-protein kinase 1; RUNX3, RUNX family transcription factor 3; SLC44A1, solute carrier 44A1; SMAD4, SMAD family member 4.
Fig. 5. Deletion of Abi3 locus alters immune response genes in 5XFAD mice. DEGs were identified in the cortices of 8-month-old male Abi3−/− mice compared to Abi3+/+ mice using the nCounter NanoString mouse (A to C) AD panel and (D to F) Neuroinflammation panel (n = 6 per genotype). Volcano plots (A and D) demonstrate the fold change (x axis) and statistical significance level expressed as the −log10 P value (y axis). The red dots represent genes up-regulated significantly more than 1.5-fold in Abi3−/− mice compared to Abi3+/+ mice. Heatmaps demonstrate the DEGs up-regulated more than 1.5-fold in Abi3−/− mice compared to Abi3+/+ mice using the (B) AD and (E) Neuroinflammation panels. Gene ontology (GO) analyses were performed for DEGs in the (C) AD panel and (F) Neuroinflammation panel using the MetaCore software. (G) Pathmap analysis was performed using MetaCore. Up-regulated genes in our dataset are shown with red circles, and down-regulated genes are shown with blue circles in the pathmap. Green arrows between nodes represent activation, while gray arrows represent interaction with no specific direction of effect. Enriched genes involved in inflammatory processes are shown in red rectangles. See also fig. S7. IL6RA, interleukin-6 receptor α; HDL, high-density lipoprotein; M-CSF, macrophage colony-stimulating factor; TNF, tumor necrosis factor; PLC-γ, phospholipase C–γ; APG7, autophagy related 7; APOA1, apolipoprotein A1; BLNK, B cell linker; C1qb, complement C1q B chain; DAP12, TYRO protein tyrosine kinase-binding protein; GATA-4, GATA binding protein 4; HDAC1, histone deacetylase 1; ITGB5, integrin subunit beta 5; MafB, MAF BZIP transcription factor B; MELC, myosin essential light chain; Rac1, Rac family small GTPase 1; RIPK1, receptor-interacting serine/threonine-protein kinase 1; RUNX3, RUNX family transcription factor 3; SLC44A1, solute carrier 44A1; SMAD4, SMAD family member 4.CC BY · PubMed Central
Fig. 6. Deletion of Abi3 locus alters the levels of immune response proteins in 5XFAD mice. Protein levels of chemokines and cytokines were measured in the PBS fraction of 8-month-old male 5XFAD mouse cortices using a 33-plex Bio-plex Pro mouse chemokine panel. (A) Among 33 proteins, 25 chemokines and cytokines were detected. Their differential protein levels are shown in the heatmap graph. (B to F) Significantly altered chemokines are shown as individual bar graphs. (B) CCL24, (C) CXCL10, (D) CCL3, and (E) CXCL16 were significantly increased, and (F) CCL25 was decreased in Abi3−/− mice compared to Abi3+/+ mice. All data were normalized by total protein level and given as means ± SEM. Unpaired t test; *P < 0.05 and **P < 0.01 (Abi3+/+, n = 5; Abi3−/−, n = 6). IFN-r, interferon receptor; IL, interleukin.
Fig. 6. Deletion of Abi3 locus alters the levels of immune response proteins in 5XFAD mice. Protein levels of chemokines and cytokines were measured in the PBS fraction of 8-month-old male 5XFAD mouse cortices using a 33-plex Bio-plex Pro mouse chemokine panel. (A) Among 33 proteins, 25 chemokines and cytokines were detected. Their differential protein levels are shown in the heatmap graph. (B to F) Significantly altered chemokines are shown as individual bar graphs. (B) CCL24, (C) CXCL10, (D) CCL3, and (E) CXCL16 were significantly increased, and (F) CCL25 was decreased in Abi3−/− mice compared to Abi3+/+ mice. All data were normalized by total protein level and given as means ± SEM. Unpaired t test; *P < 0.05 and **P < 0.01 (Abi3+/+, n = 5; Abi3−/−, n = 6). IFN-r, interferon receptor; IL, interleukin.CC BY · PubMed Central
Fig. 7. Deletion of Abi3 locus alters synaptic functions in 5XFAD mice. (A) Abi3 deficiency reduced LTP in male 5XFAD mice. (B) Data show average of normalized fEPSP slope for the final 10 min of recording (60 to 70 min) relative to 10 min baseline average. Data analyzed using one-way ANOVA and Dunnett’s multiple comparisons test; n = 5 slices from four Abi3+/+ mice, n = 7 slices from six Abi3+/− mice, and n = 7 slices from six Abi3−/− mice. Data represent means ± SEM. **P < 0.01.
Fig. 7. Deletion of Abi3 locus alters synaptic functions in 5XFAD mice. (A) Abi3 deficiency reduced LTP in male 5XFAD mice. (B) Data show average of normalized fEPSP slope for the final 10 min of recording (60 to 70 min) relative to 10 min baseline average. Data analyzed using one-way ANOVA and Dunnett’s multiple comparisons test; n = 5 slices from four Abi3+/+ mice, n = 7 slices from six Abi3+/− mice, and n = 7 slices from six Abi3−/− mice. Data represent means ± SEM. **P < 0.01.CC BY · PubMed Central
Fig. 8. Targeted scRNA-seq identifies a distinct microglia signature in Abi3−/− mice on 5XFAD background. (A) Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction plot showing 14 clusters of cells derived from 9-month-old male Abi3+/+ and Abi3−/− mouse brain (Abi3+/+, n = 6970 cells; Abi3−/−, n = 6799 cells). Top marker genes (as ranked by significance) are displayed after each cluster number in the legend. (B) Percentage of cell populations in each cluster was compared between the genotypes. Cluster 0 is the major cell population in Abi3+/+ mice, whereas cluster 1 is the major cell population in Abi3−/− mice (left). While the cells in cluster 0 significantly decreased, cluster 1 population significantly increased in Abi3−/− mice compared to Abi3+/+ mice (right). Data represent means ± SEM. Two-way ANOVA and Sidak’s multiple comparisons test; ****P < 0.0001. (C) The number of genes detected in clusters 0 and 1. (D and E) Pathway analyses were performed using the MetaCore software. Pathway analysis of (D) cluster 0–specific genes and (E) cluster 1–specific genes. CTP/UTP, cytidine 5′-triphosphate/uridine 5′-triphosphate; IFN-γ, interferon-γ; JAK-STAT, Janus kinase signal transducers and activators of transcription; MAPK, mitogen-activated protein kinase; FGFR3, fibroblast growth factor receptor 3; NF-AT, nuclear factor of activated T-cells.
Fig. 8. Targeted scRNA-seq identifies a distinct microglia signature in Abi3−/− mice on 5XFAD background. (A) Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction plot showing 14 clusters of cells derived from 9-month-old male Abi3+/+ and Abi3−/− mouse brain (Abi3+/+, n = 6970 cells; Abi3−/−, n = 6799 cells). Top marker genes (as ranked by significance) are displayed after each cluster number in the legend. (B) Percentage of cell populations in each cluster was compared between the genotypes. Cluster 0 is the major cell population in Abi3+/+ mice, whereas cluster 1 is the major cell population in Abi3−/− mice (left). While the cells in cluster 0 significantly decreased, cluster 1 population significantly increased in Abi3−/− mice compared to Abi3+/+ mice (right). Data represent means ± SEM. Two-way ANOVA and Sidak’s multiple comparisons test; ****P < 0.0001. (C) The number of genes detected in clusters 0 and 1. (D and E) Pathway analyses were performed using the MetaCore software. Pathway analysis of (D) cluster 0–specific genes and (E) cluster 1–specific genes. CTP/UTP, cytidine 5′-triphosphate/uridine 5′-triphosphate; IFN-γ, interferon-γ; JAK-STAT, Janus kinase signal transducers and activators of transcription; MAPK, mitogen-activated protein kinase; FGFR3, fibroblast growth factor receptor 3; NF-AT, nuclear factor of activated T-cells.CC BY · PubMed Central
Fig. 9. Expression of DAM genes and other cell type–specific marker genes in scRNA-seq analysis. (A to F) Targeted scRNA-seq analysis identified 14 clusters of cells derived from 9-month-old male Abi3+/+ and Abi3−/− mouse brain (Abi3+/+, n = 6970 cells; Abi3−/−, n = 6799 cells). Each plot displays the raw counts on the y axis and cluster identity on the x axis. Among the DAM marker genes, the expression of (A) Apoe, (B) Cst7, (C) Itgax, and (D) Trem2 were analyzed for each cluster. (E) Cd8a, T cell marker gene, was detected only in cluster 7. (F) Iglc3, B cell marker gene, was detected only in cluster 14. (G) Heatmap showing DAM and homeostatic microglia marker genes across microglial clusters (0 to 6 and 10). The level of gene expression is averaged per gene across all clusters; up-regulation compared to the mean expression level is shown in yellow and down-regulation in blue.
Fig. 9. Expression of DAM genes and other cell type–specific marker genes in scRNA-seq analysis. (A to F) Targeted scRNA-seq analysis identified 14 clusters of cells derived from 9-month-old male Abi3+/+ and Abi3−/− mouse brain (Abi3+/+, n = 6970 cells; Abi3−/−, n = 6799 cells). Each plot displays the raw counts on the y axis and cluster identity on the x axis. Among the DAM marker genes, the expression of (A) Apoe, (B) Cst7, (C) Itgax, and (D) Trem2 were analyzed for each cluster. (E) Cd8a, T cell marker gene, was detected only in cluster 7. (F) Iglc3, B cell marker gene, was detected only in cluster 14. (G) Heatmap showing DAM and homeostatic microglia marker genes across microglial clusters (0 to 6 and 10). The level of gene expression is averaged per gene across all clusters; up-regulation compared to the mean expression level is shown in yellow and down-regulation in blue.CC BY · PubMed Central

Verification

Claims the paper makes

42 Valid · 2 Not valid · 7 Not checked · 125 Own results and interpretations

101 more claims · 5 with their cited sources checked

Create a free account to see all 176 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 50
  • It may state two separate claims as one. 30
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

25 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 82 references

Cited by

Metadata

Authors
Karahan, H., Smith, D. C., Kim, B., Dabin, L. C., Al-Amin, M. M., Wijeratne, H. R. S., Pennington, T., Viana di Prisco, G., McCord, B., Lin, P. B.-C., Li, Y., Peng, J., Oblak, A. L., Chu, S., Atwood, B. K., & Kim, J.
Affiliations
  • Indiana University Indianapolis (US)
  • Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • St. Jude Children's Research Hospital (US)
Corresponding author
Kim, Jungsu
Venue
Science Advances
Published
2021-11-05
Volume
7
Issue
45
Pages
eabe3954-eabe3954
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3208723974
Cited by
53
References
82
Citations by year
2026: 9 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 9 · 2021: 1
FWCI
5.02
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
Funders
  • Eli Lilly and Company
  • Lilly Endowment
  • National Institutes of Health
  • School of Medicine, Indiana University
  • National Institute on Aging (R01AG054102, R01AG053500, R01AG053242, R21AG050804)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
ABI3, Alzheimer's disease, microglia, neuroinflammation, amyloid-beta deposition, gene deletion, mouse model, phagocytosis, microglial migration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.